Shin Nippon Biomedical Laboratories, Ltd. Stock Börse Stuttgart
Equities
YB3
JP3379950003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.05 EUR | +3.21% | -1.27% | -26.42% |
Sales 2024 | 26.45B 168M 155M 230M | Sales 2025 * | 30.5B 194M 179M 265M | Capitalization | 58.49B 372M 343M 508M |
---|---|---|---|---|---|
Net income 2024 | 5.53B 35.19M 32.41M 47.99M | Net income 2025 * | 4.3B 27.36M 25.2M 37.31M | EV / Sales 2024 | 2.39 x |
Net Debt 2024 * | 19.51B 124M 114M 169M | Net Debt 2025 * | 22.77B 145M 133M 198M | EV / Sales 2025 * | 2.66 x |
P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
13.6
x | Employees | - |
Yield 2024 |
3.29% | Yield 2025 * |
3.56% | Free-Float | 48.8% |
1 week | +2.55% | ||
Current month | -11.05% | ||
1 month | -8.52% | ||
3 months | -20.30% | ||
6 months | -18.69% | ||
Current year | -24.06% |
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 02-04-30 |
Terumasa Hirai
CMP | Compliance Officer | - | 84-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ichiro Nagata
BRD | Director/Board Member | 38 | 17-03-31 |
Sales & Marketing | 64 | 02-10-31 | |
Ken Takanashi
COO | Chief Operating Officer | 60 | 02-11-30 |
Date | Price | Change |
---|---|---|
24-05-28 | 8.05 | +3.21% |
24-05-27 | 7.8 | +4.00% |
24-05-24 | 7.5 | -2.60% |
24-05-23 | 7.7 | +1.99% |
24-05-22 | 7.55 | -3.82% |
Delayed Quote Börse Stuttgart, May 28, 2024 at 02:13 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- 2395 Stock
- YB3 Stock